%0 Journal Article
%T Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
%A Kiyoshi Komuta
%A Seigo Minami
%A Shouichi Ihara
%J Archive of "World Journal of Oncology".
%D 2019
%R 10.14740/wjon1179
%X Lung immune prognostic index (LIPI) was recently developed on the basis of the combination of baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH). This index was demonstrated as a specific biomarker of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). We aimed to show that LIPI may be a useful biomarker of cytotoxic chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for NSCLC
%K Lung immune prognostic index
%K Derived neutrophil to lymphocyte ratio
%K Lactate dehydrogenase
%K Non-small cell lung cancer
%K Adenocarcinoma
%K Squamous cell carcinoma
%K Epidermal growth factor receptor tyrosine kinase inhibitor
%K First-line cytotoxic chemotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396774/